| Literature DB >> 29851968 |
Raquel Burger-Calderon1,2, Karla Gonzalez2,3, Sergio Ojeda2, José Victor Zambrana2, Nery Sanchez2, Cristhiam Cerpas Cruz2,3, Harold Suazo Laguna2, Fausto Bustos1, Miguel Plazaola2, Brenda Lopez Mercado2, Douglas Elizondo2, Sonia Arguello2, Jairo Carey Monterrey2, Andrea Nuñez2,3, Josefina Coloma1,2, Jesse J Waggoner4, Aubree Gordon5, Guillermina Kuan6, Angel Balmaseda2,3, Eva Harris1.
Abstract
Zika virus (ZIKV) infection recently caused major epidemics in the Americas and is linked to congenital birth defects and Guillain-Barré Syndrome. A pilot study of ZIKV infection in Nicaraguan households was conducted from August 31 to October 21, 2016, in Managua, Nicaragua. We enrolled 33 laboratory-confirmed Zika index cases and their household members (109 contacts) and followed them on days 3-4, 6-7, 9-10, and 21, collecting serum/plasma, urine, and saliva specimens along with clinical, demographic, and socio-economic status information. Collected samples were processed by rRT-PCR to determine viral load (VL) and duration of detectable ZIKV RNA in human bodily fluids. At enrollment, 11 (10%) contacts were ZIKV rRT-PCR-positive and 23 (21%) were positive by IgM antibodies; 3 incident cases were detected during the study period. Twenty of 33 (61%) index households had contacts with ZIKV infection, with an average of 1.9 (range 1-6) positive contacts per household, and in 60% of these households, ≥50% of the members were positive for ZIKV infection. Analysis of clinical information allowed us to estimate the symptomatic to asymptomatic (S:A) ratio of 14:23 (1:1.6) among the contacts, finding 62% of the infections to be asymptomatic. The maximum number of days during which ZIKV RNA was detected was 7 days post-symptom onset in saliva and serum/plasma and 22 days in urine. Overall, VL levels in serum/plasma, saliva, and urine specimens were comparable, with means of 5.6, 5.3 and 4.5 log10 copies/ml respectively, with serum attaining the highest VL peak at 8.1 log10 copies/ml. Detecting ZIKV RNA in saliva over a similar time-period and level as in serum/plasma indicates that saliva could potentially serve as a more accessible diagnostic sample. Finding the majority of infections to be asymptomatic emphasizes the importance of silent ZIKV transmission and helps inform public health interventions in the region and globally.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29851968 PMCID: PMC6014677 DOI: 10.1371/journal.pntd.0006518
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Sample collection schedule for index cases and contacts (n = 142) among enrolled households in Managua, Nicaragua, August to October, 2016.
| Visit 0 | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | |
|---|---|---|---|---|---|---|
| Blood | X | X | X | |||
| Urine | X | X | X | X | X | X |
| Saliva | X | X | X | X | X | X |
| Blood | X | X | X | |||
| Urine | X | X | X | X | X | |
| Saliva | X | X | X | X | X | |
1Applies only to index cases: 28 from PDCS and 5 from national surveillance (n = 33). No urine or saliva samples were available for surveillance cases.
2Enrollment day for index cases and contacts.
3For the 28 index cases that were PDCS participants [32], the second and final visits correspond to a plasma sample, whereas all the other collected blood samples are serum. The 5 surveillance index cases only have an enrollment (visit 1) and final (visit 5) serum sample available.
Fig 1Flow chart of study design and enrollment for index cluster study of ZIKV infection in Managua, Nicaragua, 2016.
*One enrolled contact did not answer the individual questionnaire but fulfilled the other study requirements such as symptom questionnaire and sample donation.
Fig 2Geographic distribution of enrolled households, based on ZIKV-positive index cases from the Health Center Sócrates Flores Vivas, Managua, Nicaragua, August to October, 2016.
Demographic characteristics, ZIKV infection and symptomatic Zika status among study participants in Managua, Nicaragua, August to October, 2016.
| Characteristics | Index cases (n = 33) | Contacts (n = 109) | At enrollment ZIKV IgM+ (n = 23) | At enrollment ZIKV rRT-PCR+ (n = 11) | Incident cases (n = 3) |
|---|---|---|---|---|---|
| Age (years) | |||||
| < 15 | 28 (85) | 29 (27) | 6 (26) | 6 (55) | 1 (33) |
| ≥ 15 | 5 (15) | 80 (73) | 17 (74) | 5 (45) | 2 (67) |
| Mean | 11.4 | 30.7 | |||
| Gender | |||||
| Male | 10 (30) | 33 (30) | 7 (30) | 3 (27) | 2 (67) |
| Female | 23 (70) | 76 (70) | 16 (70) | 8 (73) | 1 (33) |
| Symptoms in ZIKV-positive contacts | |||||
| Yes | 6 (26) | 7 (64) | 1 (33) | ||
| No | 17 (74) | 4 (36) | 2 (67) | ||
1 Zika IgM-positive contacts at enrollment = single Zika IgM-positive result at visit 1.
2ZIKV rRT-PCR-positive contacts at enrollment (7 by PCR only and 4 by both rRT-PCR and IgM).
3Three post-enrollment ZIKV infections, hence incident cases, among contacts were captured by IgM conversion, but all collected bodily fluid samples remained rRT-PCR-negative throughout.
4Symptoms for ZIKV-positive contacts (n = 37) by assay (IgM or rRT-PCR) and time-point (at or post-enrollment). All enrolled ZIKV rRT-PCR confirmed index cases (n = 33) were symptomatic.
ZIKV infection positivity and percent symptomatic contacts among enrolled households in Managua, Nicaragua, August to October, 2016.
| # | House | Pos. Contacts | Total Contacts | % Positivity | Sympt. Pos. Contacts | % Sympto-matic | Incident cases |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 6 | 17 | 1 | 100 | |
| 2 | 14 | 1 | 4 | 25 | 1 | 100 | |
| 3 | 18 | 1 | 4 | 25 | 1 | 100 | |
| 4 | 20 | 1 | 4 | 25 | 0 | 0 | |
| 5 | 31 | 1 | 4 | 25 | 0 | 0 | |
| 6 | 9 | 1 | 3 | 33 | 1 | 100 | X |
| 7 | 16 | 1 | 3 | 33 | 0 | 0 | |
| 8 | 33 | 1 | 3 | 33 | 0 | 0 | |
| 9 | 7 | 1 | 2 | 50 | 0 | 0 | |
| 10 | 17 | 1 | 2 | 50 | 0 | 0 | X |
| 11 | 26 | 1 | 2 | 50 | 0 | 0 | |
| 12 | 11 | 3 | 6 | 50 | 3 | 100 | |
| 13 | 19 | 3 | 6 | 50 | 1 | 33 | |
| 14 | 5 | 2 | 3 | 67 | 1 | 50 | |
| 15 | 12 | 2 | 3 | 67 | 1 | 50 | |
| 16 | 3 | 4 | 6 | 67 | 1 | 25 | |
| 17 | 30 | 6 | 7 | 86 | 2 | 33 | X |
| 18 | 2 | 1 | 1 | 100 | 0 | 0 | |
| 19 | 23 | 1 | 1 | 100 | 1 | 100 | |
| 20 | 32 | 4 | 4 | 100 | 0 | 0 |
1 ZIKV-positive contacts: laboratory-confirmed by ZIKV RT-PCR and/or IgM ELISA.
2Symptomatic ZIKV-positive contacts: laboratory-confirmed ZIKV RT-PCR- and/or IgM-positive contacts that reported ZIKV-associated symptoms.
3 Percent of symptomatic cases among ZIKV-positive contacts in each household.
Fig 3ZIKV rRT-PCR positivity in bodily fluid samples by day post-symptom onset, collected in enrolled households in Managua, August to October, 2016.
The graph depicts ZIKV rRT-PCR positivity (%) in serum/plasma, saliva and urine over days post-symptom onset. The numbers presented in the table at the bottom are the total number of specimens processed for each bodily fluid at each time-point.
Fig 4ZIKV viral load kinetics over time in bodily fluid samples (serum/plasma, saliva and urine) by day post-symptom onset, collected in enrolled households in Managua, August to October, 2016.
Mean and standard deviation of viral load in bodily fluids plotted according to day post-symptom onset.
Risk factor analysis for ZIKV infection among contacts (n = 109).
| Risk Factor (binary) | N (%) | RR (95% CI) | aRR (95% CI) |
|---|---|---|---|
| Female | 76 (70) | 0.79 (0.50, 1.24) | 0.80 (0.51, 1.26) |
| Age, ≥15 yrs | 80 (73) | 0.70 (0.42, 1.16) | 0.68 (0.41, 1.13) |
| Contacts ≥ 4 | 60 (55) | 1.61 (0.84, 3.09) | 1.60 (0.83, 3.06) |
| Owning refrigerator | 79 (73) | 1.15 (0.59, 2.25) | NA |
| On-site water storage | 35 (32) | ||
| Outside faucet location | 64 (59) | 0.74 (0.38, 1.45) | 0.74 (0.38, 1.47) |
| Recognizing larvae/pupae | 67 (62) | 0.85 (0.43, 1.66) | 0.85 (0.43, 1.66) |
Note: Bold indicates significance at p<0.05
1Risk Ratio and 95% Confidence Interval, across households.
2Risk Ratio adjusted for owning refrigerator (SES indicator) and 95% Confidence Interval, across households.
3Contacts living in a household with 4 or more contacts.
4Not applicable.